InMode (INMD) Q1 2025: U.S. Revenue Share Drops to 50%, Exposing Macro Sensitivity
U.S. revenue share fell sharply to 50% as macro headwinds and consumer pullbacks weighed on InMode’s core market. Management’s commitment to retaining talent and investing in new platforms signals a long-term posture, but near-term visibility remains challenged by weak U.S. demand and tariff volatility. Guidance is held for now, but Q2 performance is pivotal for the full-year outlook.
Summary
- Geographic Mix Shift: International markets now match the U.S. in revenue share, highlighting regional demand divergence.
- Margin Compression: Gross and operating margins contracted as tariffs and product mix weighed on profitability.
- Critical Q2 Inflection: Full-year guidance hinges on a substantial Q2 rebound, making upcoming months decisive.
Performance Analysis
InMode’s Q1 2025 results reflect a business under acute pressure from both macro and sector-specific forces. Total revenue declined year-over-year, with U.S. sales—the company’s historical growth engine—dropping to 50% of total, down from 62-63% in prior years. This shift underscores a pronounced pullback in domestic capital equipment purchases, driven by higher interest rates on physician financing and soft consumer demand for elective aesthetic procedures.
Gross margin erosion was evident, with GAAP gross margin falling to 78% (from 80%) and non-GAAP operating margin dropping four points. The company cited U.S. tariffs (currently at 10%, with risk of reverting to 17%) as a direct drag, estimating a 2-3% margin impact. Despite these pressures, international sales—particularly in Europe—hit record levels, partially offsetting U.S. weakness. Operating expenses remained tightly controlled, with the company prioritizing workforce retention and ongoing R&D over short-term cost cuts.
- U.S. Market Contraction: Domestic sales decline outpaced international trends, shifting overall revenue mix.
- Tariff Impact: Management estimates 2-3% margin hit from U.S. import tariffs, now fully baked into guidance.
- Procedure Utilization Drop: Average treatments per installed system fell 30% over two years, reflecting deferred patient demand.
Cash flow remained positive, and the balance sheet is strong, but profitability is under sustained pressure. Management’s decision not to pass tariff costs to customers, given competitive and price-sensitive conditions, further limits near-term margin recovery.
Executive Commentary
"The medical aesthetic market continues to face headwinds driven primarily by ongoing macroeconomic uncertainty and soft consumer demand. Effective elective procedures, particularly in the surgical aesthetic segment, are often among the first to be pulled back during period of economic slowdown."
Moshe Mizrachi, CEO
"We remain committed to delivering shareholder value and returning capital to our investors in a disciplined and strategic manner. In addition, we continue to evaluate all avenues for capital allocation, including additional share purchases, potential dividends, and strategic M&A."
Yair Malka, Chief Financial Officer
Strategic Positioning
1. Talent Retention Over Short-Term Cost Cuts
InMode is prioritizing workforce stability, maintaining its sales force and R&D teams despite a sharp profitability decline. Leadership frames this as a long-term investment, aiming to preserve organizational capability for when the market rebounds. The company’s approach contrasts with peers who have pursued layoffs or aggressive cost rationalization.
2. International Diversification as a Buffer
International sales now account for 49% of total revenue, with Europe leading growth outside the U.S. Management credits recent subsidiary management changes and tighter distributor partnerships for this resilience. However, average system prices in Europe are lower and credit conditions are tightening, which could limit upside if macro headwinds persist globally.
3. Reluctance to Raise Prices Amid Tariff Pressure
Despite U.S. tariffs, InMode is holding prices steady on existing products, citing heightened price sensitivity among customers and elevated leasing rates for capital equipment. The company only takes price on new products with differentiated technology, but the overall environment limits pricing power.
4. Product Pipeline and Launch Timing Discipline
New platform launches (e.g., Ignite, Optimus Max) have not sparked the usual momentum, as market softness absorbs incremental innovation. InMode is cautious about launching its upcoming wellness platform, signaling it may delay introduction until macro visibility improves and clinical studies are complete.
5. Capital Allocation Reset
After $500 million in share repurchases with little stock price impact, management is pausing buybacks to preserve cash for potential M&A. Dividends are possible but face a 20% Israeli withholding tax, further complicating capital return calculus.
Key Considerations
Q1 2025 revealed a business at a crossroads, balancing long-term positioning with acute near-term demand and margin stress. Investors must weigh:
Key Considerations:
- U.S. Market Sensitivity: Interest rate-driven financing costs and consumer confidence are the primary demand levers for elective procedures.
- International Outperformance: Europe’s record sales and improved management provide a partial offset, but lower ASPs and tightening credit may cap future gains.
- Tariff Volatility: A shift from 10% to 17% U.S. tariffs could further compress margins, with no near-term pricing recourse.
- Utilization Headwinds: Installed base growth has not translated to higher consumable pull-through, as per-doctor procedure volumes drop.
- Capital Allocation Caution: Buybacks are paused, with management openly questioning their effectiveness and signaling potential M&A as a future lever.
Risks
InMode faces significant uncertainty around U.S. demand recovery, with management conceding they “do not see the light at the end of the tunnel” for domestic momentum. Tariff policy remains fluid, with the risk of higher rates and regulatory confusion. Competitive intensity and price sensitivity constrain the company’s ability to offset margin pressure, while international growth may not fully compensate if global macro conditions deteriorate.
Forward Outlook
For Q2 2025, InMode guided to:
- Seasonally stronger revenue, with Q2 typically representing 25-27% of annual sales
- Continued margin pressure from tariffs and geographic mix
For full-year 2025, management maintained guidance:
- Revenue: $395 million to $405 million
- Non-GAAP gross margin: 78% to 80%
- Non-GAAP operating income: $101 million to $106 million
- Non-GAAP EPS: $1.64 to $1.68
Management emphasized that holding guidance is contingent on a robust Q2 recovery. If Q2 revenue does not “significantly” exceed Q1, a downward revision is likely. Tariff assumptions are based on the current 10% rate; any increase will force a guidance update.
- Q2 is a “make-or-break” quarter for full-year outlook
- Tariff and macro policy changes remain key variables
Takeaways
Investors face a mixed landscape: U.S. market contraction and margin compression are offset by international resilience and a strong balance sheet, but near-term visibility is low and execution risk is rising.
- Revenue Mix Rebalancing: U.S. now matches international revenue, exposing the business to global, not just domestic, macro cycles.
- Margin Headwinds Persist: Tariffs and weaker utilization are not easily offset, given competitive and price-sensitive end markets.
- Q2 Is Pivotal: The next quarter will determine whether 2025 guidance is achievable or if further downside is likely.
Conclusion
InMode’s Q1 2025 underscores the challenges of navigating a cyclical, discretionary healthcare market amid macro and policy headwinds. Management’s long-term focus on talent and innovation is clear, but near-term demand and margin visibility are limited. Q2 will be decisive for both the trajectory of the business and investor confidence in the company’s outlook.
Industry Read-Through
InMode’s results reinforce the high sensitivity of the elective medical device sector to consumer confidence, interest rates, and policy shocks like tariffs. The pronounced U.S. pullback and international resilience signal that geographic diversification is increasingly critical for medtech firms. Competitors relying heavily on U.S. capital equipment sales face similar risks, while those with recurring revenue or broader procedure mix may be better insulated. Tariff uncertainty and pricing power limitations are likely to remain sector-wide headwinds, especially for companies unable to pass on cost increases in a deflationary demand environment.